Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Total Debt (2016 - 2025)

Sonoma Pharmaceuticals has reported Total Debt over the past 15 years, most recently at $56000.0 for Q3 2025.

  • For Q3 2025, Total Debt fell 31.71% year-over-year to $56000.0; the TTM value through Sep 2025 reached $56000.0, down 31.71%, while the annual FY2025 figure was $220000.0, 31.89% down from the prior year.
  • Total Debt for Q3 2025 was $56000.0 at Sonoma Pharmaceuticals, down from $139000.0 in the prior quarter.
  • Over five years, Total Debt peaked at $1.9 million in Q1 2021 and troughed at $15000.0 in Q4 2022.
  • A 5-year average of $346764.7 and a median of $220000.0 in 2025 define the central range for Total Debt.
  • On a YoY basis, Total Debt climbed as much as 296.26% in 2021 and fell as far as 85.36% in 2021.
  • Year by year, Total Debt stood at $199000.0 in 2021, then crashed by 92.46% to $15000.0 in 2022, then surged by 193.33% to $44000.0 in 2023, then skyrocketed by 86.36% to $82000.0 in 2024, then tumbled by 31.71% to $56000.0 in 2025.
  • Business Quant data shows Total Debt for SNOA at $56000.0 in Q3 2025, $139000.0 in Q2 2025, and $220000.0 in Q1 2025.